

<https://doi.org/10.1038/s41467-019-08770-5>

OPEN

Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103⁺ dendritic cell differentiation

Jun Yan^{1,2,3}, Qingnan Zhao³, Konrad Gabrusiewicz⁴, Ling-Yuan Kong⁴, Xueqing Xia³, Jian Wang⁵, Martina Ott⁴, Jingda Xu⁶, R. Eric Davis⁶, Longfei Huo³, Ganesh Rao⁴, Shao-Cong Sun⁷, Stephanie S. Watowich⁷, Amy B. Heimberger⁴ & Shulin Li³

Correction to: *Nature Communications* <https://doi.org/10.1038/s41467-018-08271-x>, published online 25 Jan 2019.

The original version of this Article contained errors in the author affiliations.

Qingnan Zhao, Xueqing Xia, Longfei Huo and Shulin Li were incorrectly associated with Beijing Institute for Brain Disorders, 100069, Beijing, China.

This has now been corrected in both the PDF and HTML versions of the Article.

Published online: 15 February 2019



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹Center for Brain Disorders Research, Capital Medical University, Beijing 100069, China. ²Beijing Institute for Brain Disorders, Beijing 100069, China. ³Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁴Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁵Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁶Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁷Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Correspondence and requests for materials should be addressed to A.B.H. (email: ahimber@mdanderson.org) or to S.L. (email: sli4@mdanderson.org)